There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
NCT04676529
Recruiting
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/28/2024
Locations: Comprehensive Cancer Center (UAB CCC), Birmingham, Alabama
Conditions: Myelofibrosis
Register for Updates
A Study of STAR-0215 in Participants With Hereditary Angioedema
NCT05695248
Recruiting
The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Allervie Clinical Research, Birmingham, Alabama
Conditions: Hereditary Angioedema
Register for Updates
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
NCT05254834
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: Central Alabama Research, Birmingham, Alabama +1 locations
Conditions: Cancer
Register for Updates
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044
Recruiting
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: The University of Alabama at Birmingham (UAB), Birmingham, Alabama
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568
Recruiting
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Gender:
All
Ages:
80 years and below
Trial Updated:
04/25/2024
Locations: University Of Alabama At Birmingham, Birmingham, Alabama
Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Register for Updates
Food Delivery, Remote Monitoring, and Coaching-Enhanced Education for Optimized Diabetes Management (FREEDOM)
NCT05288452
Recruiting
Brief Summary: The FREEDOM study aims to develop a scalable intervention to improve type 2 diabetes mellitus control in low-income Black adults in the Deep South. The intervention targets social determinants of health (SDoH) such as reduced healthcare access, poverty, transportation barriers, and food insecurity.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: UAB Hospital and UMMC Cardiology Clinics, Birmingham, Alabama
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
NCT04061135
Recruiting
The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor sympto... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Movement Disorders
Register for Updates
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
NCT05927974
Recruiting
The purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. Cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: ADD, depression). The investigators are interested in the brain activity related to these issues, and wa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Dementia, ADD, Depression
Register for Updates
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Recruiting
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
04/24/2024
Locations: The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
Respiratory Outcomes After Early Vitamin D Supplementation in Infants Born Extremely Preterm
NCT05615311
Recruiting
This is a masked randomized clinical trial in which extremely preterm infants fed human milk will be randomly assigned to receive either the highest (intervention group) or lowest (control group) vitamin D dose recommended during the first 14 days after birth.
Gender:
All
Ages:
Between 1 day and 4 days
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Prematurity; Extreme
Register for Updates
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT04332588
Recruiting
The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with brea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: HER2-positive Breast Cancer
Register for Updates